Specialty Chemical Company Tatva Chintan Pharma Chem has doubled investor money on the day of registration, with the stock of 129.6% to strike a high intraday of 2,486.30 rupees, on July 29th. Most experts advise to keep the stock for the long term in view of the health of society. Financials, global presence and solid product portfolio. Investors in the short term, however, can reserve partial benefits, they said.
The stock opened at 2,111.80 RS on BSE, up 95% on the issue price of 1,083 rupees. It was 2,304.35 Rupees, up 112.77%, with volumes of 6.38 equity shares LAKH at the time of publication of this copy.
With more than 100% of earnings, this is one of the strongest lists of 2021. GR Infraprojects rallied 108.7% and Indigo paints rose 109.31% on the day of the list.
“Given its important product portfolio, its overall competence and its healthy balance sheet, it is a long-term bet. As a result, investors can consider holding this issue for the next 3 to 5 years”, Declared Likhita Chepa, Senior Analyst of CapitalVia Global Research.
Prashanth Tapse, VP Research, Mehta Equities, also advised allômes to keep in stock. The market always rewards a player who has the high growth potential and if investors want to add the stock of the day of registration, they can do so so as to keep a long-term vision.
“We assume that Tatva Chintan is well placed to exploit changing global demand in India by having an expertise of personalized solutions in specialized chemicals. We are optimistic about the sector and expect export opportunities for robust multi-year export exports. China as well as local demand in the current, “says Tapse.
With only two three players on the domestic market, Tatva Chintan has the opportunity to expand and explore the world market, he said.
“Tatva Chintan is good for gaining favorable and supportive growth to conduct sustainable activities as well as the profitable growth of the long-term average, as it has a well-diversified presence in the pharmaceutical, agrochemical and agrochemical industry and Automotive, “he said.
Given a portfolio of diversified products with high input barriers in segments, a global presence with a wide customer base focusing on “green” chemistry processes and reasonable assessments, capping has a positive perspective on Tatva Chintan.
Tatva Chintan raised a Crore of Rs 500 through his public question subscribed to 180.35 times during July 16th.
The company manufactures a guideline (SDAS), phase transfer catalyst (PTC), electrolyte salts for super capacitor batteries and pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC). The company is the largest and only commercial commercial manufacturer of SDAS for zeolites in India.
In addition to its customers in India, the company also exports its products to more than 25 countries, including the United States, China, Germany, Japan, South Africa and the United Kingdom. During the 20021 fiscal year, exports of products amounted to 211.99 crore, which accounted for 70.58% of the Company’s revenues from operations.
Astha-Jain, Senior Research Analyst at OREM Securities, recommended booking partial benefits if the stock trades more than 90 to 95% and maintains a long-term partial allocation, the company being one of the world’s leading producers a full range of PTC. In India and one of the leading producers around the world with a broad clientele have strong future prospects.
Disclaimer: The points of view and investment advice expressed by experts on MoneyControl.com are his and not the website or management. MoneyControl.com advises users to check with certified experts before making investment decisions.
